PubRank

Scott Stawicki

Author PubWeight™ 37.40‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006 6.56
2 Therapeutic antibody targeting of individual Notch receptors. Nature 2010 4.56
3 Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007 4.11
4 PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science 2008 3.86
5 Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008 2.35
6 A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011 2.14
7 Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med 2011 2.10
8 Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009 1.89
9 Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO J 2007 1.43
10 Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One 2010 1.34
11 Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Dev Cell 2011 1.29
12 Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 2006 1.29
13 Structural basis for the dual recognition of helical cytokines IL-34 and CSF-1 by CSF-1R. Structure 2012 1.21
14 Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement. J Biol Chem 2009 1.09
15 Structural insight into distinct mechanisms of protease inhibition by antibodies. Proc Natl Acad Sci U S A 2007 1.05
16 Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci Transl Med 2013 1.01
17 MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J 2010 0.91